Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELDN Eledon Pharmaceuticals, Inc.

Market Closed 07-31 16:00:00 EDT

3.38

-0.03

-0.88%

盘后3.44

+0.06+1.78%

19:39 EDT

High3.49	Low3.26	Vol642.16K
Open3.41	D1 Closing3.41	Amplitude6.91%
Mkt Cap260.89M	Tradable Cap239.08M	Total Shares77.19M
T/O2.15M	T/O Rate0.91%	Tradable Shares70.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELDN","market":"US","secType":"STK","nameCN":"Eledon Pharmaceuticals, Inc.","latestPrice":3.38,"timestamp":1785528000000,"preClose":3.41,"halted":0,"volume":642163,"hourTrading":{"tag":"盘后","latestPrice":3.44,"preClose":3.38,"latestTime":"19:39 EDT","volume":7510,"amount":25261.5456,"timestamp":1785541147340,"change":0.06,"changeRate":0.017751,"amplitude":0.038462},"delay":0,"changeRate":-0.008797653958944354,"floatShares":70733600,"shares":77187800,"eps":-0.860885,"marketStatus":"Market Closed","change":-0.03,"latestTime":"07-31 16:00:00 EDT","open":3.41,"high":3.4905,"low":3.255,"amount":2147804.698483,"amplitude":0.069062,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.860885,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":3.41,"preHourTrading":{"tag":"盘前","latestPrice":3.42,"preClose":3.41,"latestTime":"09:25 EDT","volume":531,"amount":1839.679767,"timestamp":1785504300025,"change":0.01,"changeRate":0.002933,"amplitude":0.096774},"postHourTrading":{"tag":"盘后","latestPrice":3.44,"preClose":3.38,"latestTime":"19:39 EDT","volume":7510,"amount":25261.5456,"timestamp":1785541147340,"change":0.06,"changeRate":0.017751,"amplitude":0.038462},"volumeRatio":0.4911236593229139,"impliedVol":1.0487,"impliedVolPercentile":0.3386},"requestUrl":"/m/hq/s/ELDN/tweets","defaultTab":"tweets","newsList":[{"id":"2655369246","title":"NewcelX Prices USD 1.4 Million Private Placement at USD 4.03 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2655369246","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655369246?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:00","pubTimestamp":1785502836,"startTime":"0","endTime":"0","summary":"NewcelX prices USD 1.4 million private placement at USD 4.03 per shareNewcelX priced a USD 1.4 million private placement at USD 4.03 per share, a 20% premium to the July 30 close.Deal covers 347,134 c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL9Dppng:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4112","LU2095319765.USD","ELDN","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","SG9999014005.SGD","BK4585","IE00B64PRP62.GBP","BCDF","IE00BN0W2T93.GBP","NDAQ","NCEL","IE00BN0W2V16.EUR","SG9999014021.USD","BK4588","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654051589","title":"Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2654051589","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654051589?lang=en_us&edition=fundamental","pubTime":"2026-07-25 20:14","pubTimestamp":1784981685,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eldn/eledon-pharmaceuticals/news/heres-why-were-watching-eledon-pharmaceuticals-nasdaqeldn-ca-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eldn/eledon-pharmaceuticals/news/heres-why-were-watching-eledon-pharmaceuticals-nasdaqeldn-ca-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONEQ","FTEC","SQQQ","BK4139","JEPQ","QQQJ","QQQY","NQmain","PSQ","QQQE","QQQA","NVIW.SI","IYW","NDX","GPIQ","QQQM",".IXIC","TQQY","ELDN","QYLG","QQQ","TECS","QLD","MNQmain","TQQQ","QDTE","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653272294","title":"Eledon Pharmaceuticals Initiated at Buy by Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2653272294","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653272294?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:03","pubTimestamp":1784635380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ELDN/analyst-ratings(END) Dow Jones NewswiresJuly 21, 2026 08:03 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646735874","title":"Natera Partners with Eledon to Supply Prospera Monitoring for Planned Phase 3 Kidney Transplant Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2646735874","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646735874?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:00","pubTimestamp":1782385246,"startTime":"0","endTime":"0","summary":"Natera partners with Eledon to supply Prospera monitoring for planned Phase 3 kidney transplant trialNatera entered a strategic partnership with Eledon to use Prospera as the exclusive dd-cfDNA monito","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL6XlYQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261612.USD","LU2065170008.USD","LU2065171311.SGD","LU2264538146.SGD","LU0963586101.USD","ELDN","LU1064131342.USD","LU1988902786.USD","LU0053671581.USD","LU2065731478.USD","LU0012050646.USD","LU0345770993.USD","BK4139","LU2065169927.USD","LU0345770308.USD","LU2324357040.USD","LU2065171402.SGD","NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646874713","title":"Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646874713?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:00","pubTimestamp":1782385201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA7WBQ4V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0106261612.USD","LU2065170008.USD","NTRA","LU2264538146.SGD","LU1988902786.USD","LU2065731478.USD","LU1064131342.USD","BK4139","LU0345770993.USD","ELDN","LU0963586101.USD","LU2065171402.SGD","LU2065171311.SGD","LU0012050646.USD","LU0345770308.USD","LU0053671581.USD","LU2324357040.USD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646772874","title":"Natera - Eledon to Initiate Phase 3 Kidney Transplant Trial in Late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2646772874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646772874?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:00","pubTimestamp":1782385201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA7WBQ4V:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0012050646.USD","LU1988902786.USD","LU0345770308.USD","LU2065169927.USD","LU0053671581.USD","ELDN","LU2065170008.USD","LU2264538146.SGD","LU2065171402.SGD","BK4139","LU2065171311.SGD","LU2324357040.USD","LU2065731478.USD","LU0963586101.USD","LU0106261612.USD","LU0345770993.USD","NTRA","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645856550","title":"Health Rounds: Drug to prevent organ rejection after kidney transplant tops standard treatment in trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645856550","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645856550?lang=en_us&edition=fundamental","pubTime":"2026-06-24 03:21","pubTimestamp":1782242488,"startTime":"0","endTime":"0","summary":"Health Rounds: Drug to prevent organ rejection after kidney transplant tops standard treatment in trialHealth Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy LapidJune 23  - Hello Health Rounds readers!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nL1N42V0SF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835827","title":"Guggenheim Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835827","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835827?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:33","pubTimestamp":1782214435,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from Guggenheim reiterated a Buy rating on Eledon Pharmaceuticals, with a price target of $8.00. The company’s shar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645023070","title":"Eledon Pharmaceuticals shareholders approve increase in authorized common shares to 450 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2645023070","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645023070?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:00","pubTimestamp":1782162054,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals held its annual shareholder meeting on June 18, 2026.Shareholders authorized an amendment to raise authorized common shares to 450,000,000 from 300,000,000; the amendment was later filed effective June 22, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL75g5Vs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645624079","title":"Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN) and MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645624079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645624079?lang=en_us&edition=fundamental","pubTime":"2026-06-23 00:30","pubTimestamp":1782145813,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eledon Pharmaceuticals (ELDN) and MoonLake Immunothe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eledon-pharmaceuticals-eldn-and-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eledon-pharmaceuticals-eldn-and-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4581","LABU","LU0128526141.USD","HCSG","MLTX","XLV","XBI","LU0029874061.USD","BK4588","BK4585","BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022871","title":"Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022871","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022871?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:20","pubTimestamp":1782130817,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals  said Monday that new long-term mid-stage data showed tegoprubart had sustained higher kidney function and improved patient-reported outcomes in kidney transplant patients than tacrolimus.At 18 months, tegoprubart-treated patients maintained higher mean estimated glomerular filtration rate over time, the clnical-stage company said.Eledon said no biopsy-proven acute rejection events occurred in tegoprubart-treated patients after the first six months of treatment, while seven events were reported in the tacrolimus arm after six months.The company said it plans to begin late-stage development of tegoprubart  late this year.Shares of the company were up more than 2% in recent Monday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645006024","title":"Eledon posts American Transplant Congress presentation on tegoprubart kidney transplant data update","url":"https://stock-news.laohu8.com/highlight/detail?id=2645006024","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645006024?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:17","pubTimestamp":1782130627,"startTime":"0","endTime":"0","summary":"Eledon highlighted kidney transplant data showing tegoprubart delivered a statistically significant eGFR advantage versus tacrolimus by month 18, about 12 points.eGFR spread widened to about 10 points at month 21, about 19 points at month 24, supporting a potential durability benefit versus calcineurin inhibitors.BESTOW long-term extension showed no biopsy-proven acute rejection on tegoprubart after the first 6 months; tacrolimus recorded most rejections beyond 6 months.Phase 3 kidney transplant study planned with about 600 patients, primary endpoint non-inferiority on composite efficacy failure at 12 months versus tacrolimus.University of Chicago islet cell trial reported 12 of 12 patients achieved insulin independence, no severe hypoglycemic events post-transplant, HbA1c fell about 2.6%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL3sqN90:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645102990","title":"Eledon says Phase 2 BESTOW extension shows higher kidney function with tegoprubart vs tacrolimus at 18 months","url":"https://stock-news.laohu8.com/highlight/detail?id=2645102990","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645102990?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:01","pubTimestamp":1782126112,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals reported long-term Phase 2 BESTOW extension results for tegoprubart in kidney transplant patients, presented at the American Transplant Congress.The drug sustained better kidney function over time versus tacrolimus, with no late acute rejection events seen beyond the early post-transplant period.Patient-reported outcomes favored tegoprubart, indicating lower symptom burden versus tacrolimus.Safety trends favored tegoprubart, with fewer central nervous system and kidney-related adverse events reported than with tacrolimus.Eledon plans to start Phase 3 kidney transplant development in late 2026, targeting a non-inferiority endpoint versus tacrolimus at 52 weeks.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLNRlff:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","IE00BN0W2W23.USD","BK4139","LU2095319765.USD","IE00BKPKM429.USD","BK4585","BK4112","LU0314104364.USD","SG9999014021.USD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BN0W2V16.EUR","ELDN","IE00BGHQF748.EUR","NDAQ","LU2210150020.SGD","SG9999014005.SGD","BK4588","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029618","title":"Eledon Presents Long-Term Extension Phase 2 Bestow Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes With Tegoprubart Compared With Tacrolimus","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029618","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029618?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA4CHLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642420142","title":"Noble Financial Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642420142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642420142?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:25","pubTimestamp":1781108740,"startTime":"0","endTime":"0","summary":"In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Eledon Pharmaceuticals, with a price target of $10.00. L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-its-buy-rating-for-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-its-buy-rating-for-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELDN","NBL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641489560","title":"Eledon Pharmaceuticals announces updated results from tegoprubart trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2641489560","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641489560?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:17","pubTimestamp":1780917425,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals (ELDN) announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eledon-pharmaceuticals-announces-updated-results-from-tegoprubart-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eledon-pharmaceuticals-announces-updated-results-from-tegoprubart-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641486932","title":"Eledon Announces Updated Data From Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients With Type 1 Diabetes (T1d) at Uchicago Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2641486932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641486932?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:00","pubTimestamp":1780916401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUA9NW8W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641616201","title":"Eledon says updated tegoprubart islet transplant trial data to be presented at ADA 2026 sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2641616201","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641616201?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:31","pubTimestamp":1780605108,"startTime":"0","endTime":"0","summary":"Eledon flagged updated results from an investigator-run islet transplant trial of tegoprubart in Type 1 diabetes, scheduled for presentation June 7, 2026.The readout will focus on whether anti-CD40L therapy supported islet graft survival and sustained function, indicating potential to reduce reliance on broader immunosuppression.The presentation keeps tegoprubart in view as Eledon expands its transplant-focused pipeline, supporting strategic optionality across multiple organ and cell-therapy settings.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL8PGw6m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","NDAQ","BK4112","IE00B64PRP62.GBP","LU0314104364.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4588","BK4585","LU2095319765.USD","SG9999014005.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","ELDN","SG9999014013.SGD","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637022317","title":"Analysts Offer Insights on Healthcare Companies: Whitehawk Therapeutics (WHWK) and Eledon Pharmaceuticals (ELDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637022317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637022317?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:00","pubTimestamp":1779458442,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Whitehawk Therapeutics (WHWK) and Eledon Pharmaceuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-whitehawk-therapeutics-whwk-and-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-whitehawk-therapeutics-whwk-and-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4139","BK4585","LU0128526141.USD","BK4588","HCSG","WHWK","XLV","ELDN","BK4581","BK4137","LU0029874061.USD","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878548","title":"Eledon presents new long-term Phase 2 BESTOW kidney transplant data for tegoprubart at ATC","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878548","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878548?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:06","pubTimestamp":1779307599,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals scheduled new long-term data from its Phase 2 BESTOW kidney transplant program for presentation at the American Transplant Congress in Boston on June 20-24, 2026.The update will cover longer follow-up from tegoprubart studies aimed at preventing kidney transplant rejection, with a focus on safety and efficacy outcomes.An oral presentation is set for June 22, 2026, with an accompanying conference call the same morning to discuss the updated BESTOW results and extension-study findings.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL6VFXFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014021.USD","BK4588","LU2095319765.USD","SG9999014005.SGD","BK4585","BK4112","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","ELDN","SG9999014039.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","NDAQ","SG9999014013.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eledon.com","stockEarnings":[{"period":"1week","weight":-0.0559},{"period":"1month","weight":-0.1333},{"period":"3month","weight":-0.084},{"period":"6month","weight":0.5364},{"period":"1year","weight":0.073},{"period":"ytd","weight":1.2384}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.166113},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.000872},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.044379},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009056},{"month":5,"riseRate":0.583333,"avgChangeRate":0.748048},{"month":6,"riseRate":0.25,"avgChangeRate":-0.164848},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.086359},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.035259},{"month":9,"riseRate":0.272727,"avgChangeRate":0.085532},{"month":10,"riseRate":0.5,"avgChangeRate":2.263696},{"month":11,"riseRate":0.5,"avgChangeRate":-0.069266},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.094259}],"exchange":"NASDAQ","name":"Eledon Pharmaceuticals, Inc.","nameEN":"Eledon Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eledon Pharmaceuticals, Inc.(ELDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eledon Pharmaceuticals, Inc.,ELDN,Eledon Pharmaceuticals, Inc.股票,Eledon Pharmaceuticals, Inc.股票老虎,Eledon Pharmaceuticals, Inc.股票老虎国际,Eledon Pharmaceuticals, Inc.行情,Eledon Pharmaceuticals, Inc.股票行情,Eledon Pharmaceuticals, Inc.股价,Eledon Pharmaceuticals, Inc.股市,Eledon Pharmaceuticals, Inc.股票价格,Eledon Pharmaceuticals, Inc.股票交易,Eledon Pharmaceuticals, Inc.股票购买,Eledon Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eledon Pharmaceuticals, Inc.(ELDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction